TSX Exchange Symbol: RVX
CALGARY, Feb. 10, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) presented at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 held at the Waldorf Astoria in New York City. The presentation was a corporate update on the proposed Phase III clinical trial and business structure options.
The presentation was archived and can be viewed using the following link: http://www.veracast.com/webcasts/bio/ceoinvestor2015/09110256932.cfm
About the BIO CEO & Investor Conference
The 17th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. The 2014 CEO & Investor Conference featured 1,820 partnering meetings, 149 company presentations, and 1,400 attendees, over half of which were investors.
Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease, and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on Twitter @Resverlogix_RVX and our blog at http://www.resverlogix.com/blog.
For further information, please contact:
Donald J. McCaffrey
President and CEO
Director, Investor Relations & Corporate Communications
SOURCE Resverlogix Corp.